BR112014000352A2 - método de purificar uma proteína de fusão-fc, proteínas de fusão contendo fc purificada, tnfr:fc purificada, e tnfr:fc elevadamente purificada - Google Patents

método de purificar uma proteína de fusão-fc, proteínas de fusão contendo fc purificada, tnfr:fc purificada, e tnfr:fc elevadamente purificada

Info

Publication number
BR112014000352A2
BR112014000352A2 BR112014000352A BR112014000352A BR112014000352A2 BR 112014000352 A2 BR112014000352 A2 BR 112014000352A2 BR 112014000352 A BR112014000352 A BR 112014000352A BR 112014000352 A BR112014000352 A BR 112014000352A BR 112014000352 A2 BR112014000352 A2 BR 112014000352A2
Authority
BR
Brazil
Prior art keywords
purified
tnfr
purifying
protein
proteins containing
Prior art date
Application number
BR112014000352A
Other languages
English (en)
Portuguese (pt)
Inventor
Lee Christine
Cynthia Ikechukwu Ijeoma
Nti-Gyabaah Joseph
Petroff Matthew
Original Assignee
Merck Sharp & Dohe Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohe Corp filed Critical Merck Sharp & Dohe Corp
Publication of BR112014000352A2 publication Critical patent/BR112014000352A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
BR112014000352A 2011-07-08 2012-07-03 método de purificar uma proteína de fusão-fc, proteínas de fusão contendo fc purificada, tnfr:fc purificada, e tnfr:fc elevadamente purificada BR112014000352A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161505710P 2011-07-08 2011-07-08
PCT/US2012/045339 WO2013009526A1 (en) 2011-07-08 2012-07-03 Method for purifying fc-fusion protein

Publications (1)

Publication Number Publication Date
BR112014000352A2 true BR112014000352A2 (pt) 2017-02-14

Family

ID=47506409

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014000352A BR112014000352A2 (pt) 2011-07-08 2012-07-03 método de purificar uma proteína de fusão-fc, proteínas de fusão contendo fc purificada, tnfr:fc purificada, e tnfr:fc elevadamente purificada

Country Status (10)

Country Link
US (1) US9556258B2 (https=)
EP (1) EP2729482B1 (https=)
JP (1) JP6280499B2 (https=)
KR (1) KR20140043934A (https=)
CN (1) CN103814044A (https=)
AU (2) AU2012282960A1 (https=)
BR (1) BR112014000352A2 (https=)
CA (1) CA2840951A1 (https=)
DK (1) DK2729482T3 (https=)
WO (1) WO2013009526A1 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014009146A8 (pt) 2011-10-18 2017-06-20 Coherus Biosciences Inc formulações de etanercepte estabilizadas com aminoácidos
SI2895188T1 (en) 2012-09-11 2018-05-31 Coherus Biosciences, Inc. CORRECTED QUALITY ETHANERCEPT WITH HIGH QUALITY AND EXCELLENT EXPERIENCE
SI3395423T1 (sl) 2013-03-14 2023-12-29 Amgen Inc. Odstranjevanje izluženega liganda za afinitetno čiščenje
SG10201802023RA (en) * 2013-03-26 2018-05-30 Coherus Biosciences Inc Protein production method
WO2015120056A1 (en) * 2014-02-04 2015-08-13 Biogen Ma Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
PL3137209T3 (pl) 2014-05-02 2023-01-02 W.R. Grace & Co. - Conn. Funkcjonalizowany materiał nośnikowy i sposoby wytwarzania oraz stosowania funkcjonalizowanego materiału nośnikowego
EP4218991A1 (en) 2014-05-13 2023-08-02 Amgen Inc. Process control systems and methods for use with filters and filtration processes
MX2016016318A (es) * 2014-06-13 2017-06-12 Lupin Atlantis Holdings Sa Proceso para la purificacion de la proteina de fusion.
FR3025515B1 (fr) * 2014-09-05 2016-09-09 Lab Francais Du Fractionnement Procede de purification d'un anticorps monoclonal
WO2016065273A1 (en) * 2014-10-24 2016-04-28 The University Of Chicago Heat-inducible self-assembling protein domains
US20160130324A1 (en) 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
EP3241849A4 (en) 2014-12-31 2018-06-20 LG Chem, Ltd. Method for producing tnfr-fc fusion protein containing target content of impurities
KR102566292B1 (ko) * 2015-06-05 2023-08-10 더블유.알. 그레이스 앤드 캄파니-콘. 흡착성 바이오프로세싱 정화제와 이의 제조 및 사용 방법
EP3699269A1 (en) 2015-09-22 2020-08-26 F. Hoffmann-La Roche AG Expression of fc-containing proteins
US20170101435A1 (en) * 2015-10-13 2017-04-13 Therapeutic Proteins International, LLC Harvesting and perfusion apparatus
CN108463243B (zh) 2015-11-19 2022-06-14 夏尔人类遗传性治疗公司 重组人c1酯酶抑制剂及其用途
WO2017194592A1 (en) 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Method of storing a separation matrix
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
WO2017194593A1 (en) 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Method of cleaning and/or sanitizing a separation matrix
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10513537B2 (en) 2016-05-11 2019-12-24 Ge Healthcare Bioprocess R&D Ab Separation matrix
KR102579850B1 (ko) * 2016-07-22 2023-09-18 암젠 인크 Fc-함유 단백질의 정제 방법
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
CN109929038B (zh) * 2017-12-15 2020-10-09 山东博安生物技术有限公司 Vegf捕获剂融合蛋白的纯化方法
CN109929027B (zh) * 2017-12-15 2020-10-09 山东博安生物技术有限公司 采用线性洗脱步骤的重组融合蛋白纯化方法
EP3941607A1 (en) * 2019-03-21 2022-01-26 Codiak BioSciences, Inc. Process for preparing extracellular vesicles
IL292940A (en) * 2019-11-22 2022-07-01 Morphosys Ag Collection of extractant during antibody chromatography
AU2021262609A1 (en) 2020-05-01 2022-12-22 Kashiv Biosciences, Llc An improved process of purification of protein
US11416468B2 (en) * 2020-07-21 2022-08-16 International Business Machines Corporation Active-active system index management
CN112574321B (zh) * 2020-12-30 2023-10-20 上海赛金生物医药有限公司 一种捕获单克隆抗体-肿瘤坏死因子融合蛋白的亲和纯化方法
EP4291246A4 (en) * 2021-02-11 2024-12-11 Denali Therapeutics Inc. ANTI-TRANSFERRIN RECEPTOR FUSION PROTEINS AND METHODS OF USE THEREOF
US20240400612A1 (en) * 2021-09-28 2024-12-05 Kashiv Biosciences, Llc An improved process for purification of fusion protein
AU2022358612A1 (en) * 2021-09-28 2024-04-11 Kashiv Biosciences, Llc An improved process of purification of fusion protein
CN114891061A (zh) * 2022-04-25 2022-08-12 杭州艾策生物技术有限公司 一种糖基化重组蛋白的纯化方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5927398A (en) * 1997-01-21 1998-08-07 Human Genome Sciences, Inc. Fc receptors and polypeptides
EP1006183A1 (en) * 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
ES2322945T5 (es) * 2001-12-21 2012-10-17 Immunex Corporation Métodos para purficación de proteína
EP1543106B1 (en) * 2002-07-15 2007-04-11 Immunex Corporation Methods and media for controlling sialylation of proteins produced by mammalian cells
GB0304576D0 (en) 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
US7427659B2 (en) 2003-10-24 2008-09-23 Amgen Inc. Process for purifying proteins in a hydrophobic interaction chromatography flow-through fraction
US20090105455A1 (en) * 2004-04-14 2009-04-23 Andreas Herrmann Purified interleukin-15/fc fusion protein and preparation thereof
JP2010501622A (ja) * 2006-08-28 2010-01-21 アレス トレーディング ソシエテ アノニム Ｆｃ−融合タンパク質の精製法
WO2008025747A1 (en) * 2006-08-28 2008-03-06 Ares Trading S.A. Process for the purification of fc-fusion proteins
WO2008085988A1 (en) * 2007-01-05 2008-07-17 Amgen Inc. Methods of purifying proteins
SG177202A1 (en) * 2008-09-15 2012-01-30 Emd Millipore Corp Methods for quantifying protein leakage from protein based affinity chromatography resins
US20120282654A1 (en) 2009-04-29 2012-11-08 Schering Corporation Antibody purification
EP2462157B1 (en) * 2009-08-07 2020-06-17 EMD Millipore Corporation Methods for purifying a target protein from one or more impurities in a sample
US9540426B2 (en) * 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production

Also Published As

Publication number Publication date
AU2012282960A1 (en) 2014-01-16
CA2840951A1 (en) 2013-01-17
EP2729482A4 (en) 2015-02-25
DK2729482T3 (en) 2018-05-07
US9556258B2 (en) 2017-01-31
JP6280499B2 (ja) 2018-02-14
WO2013009526A1 (en) 2013-01-17
EP2729482A1 (en) 2014-05-14
AU2017204893A1 (en) 2017-08-03
KR20140043934A (ko) 2014-04-11
EP2729482B1 (en) 2018-03-07
US20140187751A1 (en) 2014-07-03
CN103814044A (zh) 2014-05-21
JP2014520814A (ja) 2014-08-25

Similar Documents

Publication Publication Date Title
BR112014000352A2 (pt) método de purificar uma proteína de fusão-fc, proteínas de fusão contendo fc purificada, tnfr:fc purificada, e tnfr:fc elevadamente purificada
IL276534A (en) Methods for the purification of fusion proteins containing serphin
DK2691411T3 (da) Buffersystem til proteinoprensning
BR112013024521A2 (pt) métodos de purificação de proteínas
DK2526114T3 (da) Kromatografisk fremgangsmåde til oprensning af FC-indeholdende proteiner
DK2598516T3 (da) Fremgangsmåde til proteinoprensning
WO2013138793A3 (en) Affinity reagants for protein purification
IL225650A0 (en) Protein purification processes
PT2768857T (pt) Métodos para purificar anticorpos
PL3299380T3 (pl) Sposoby oczyszczania polipeptydów
DK2598514T3 (da) Proteinoprensning
DK3578659T3 (da) Kunstige nukelinsyremolekyler til forbedret protein- eller peptidekspression
EP2663857A4 (en) Protein Detection Method
BR112014011900A2 (pt) um método de purificação de anticorpo
PL3415531T3 (pl) Białka wiążące antygen
SMT202400377T1 (it) Proteine contenenti fc di anticorpi eterodimerici e metodi per la loro produzione
EP2953965A4 (en) PROTEIN PURIFICATION PROCESS
BR112014001120A2 (pt) métodos de separação de polipeptídeos
EP2727930A4 (en) PROCESS FOR CLEANING PROTEINS
PL2776460T3 (pl) Białko fuzyjne zawierające interleukinę 4 i interleukinę 10
EP2698386A4 (en) FUSION PROTEIN
SG10201606218WA (en) Purified Proteins
BR112015009462A2 (pt) composição farmacêutica estável do tnfr:fc proteína de fusão
IL233999A0 (en) Ligands for binding antibodies and protein conjugates containing antibodies and their use in chromatography
IL228491A0 (en) Methods for the purification of viruses using gel permeation chromatography

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2594 DE 24-09-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.